Screener
Bristol-Myers Squibb BMY Sprycel — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| Dollars in millions | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Eliquis | 4,481 | 3,680 | 8,617 | 7,245 |
| Revlimid | 425 | 838 | 773 | 1,774 |
| Pomalyst/Imnovid | 204 | 708 | 717 | 1,366 |
| Sprycel | 88 | 120 | 160 | 295 |
| Abraxane | 55 | 105 | 105 | 210 |
| Other Legacy products(b) | 170 | 223 | 326 | 421 |
| Total Legacy Portfolio | 5,422 | 5,673 | 10,699 | 11,311 |
| Other revenue(c) | (9) | — | (23) | — |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's sprycel — total revenues?
- Bristol-Myers Squibb (BMY) reported sprycel — total revenues of $88M in Q2 2026.
- How has Bristol-Myers Squibb's sprycel — total revenues changed year-over-year?
- Bristol-Myers Squibb's sprycel — total revenues decreased by 26.7% year-over-year, from $120M to $88M.
- What is the long-term trend for Bristol-Myers Squibb's sprycel — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's sprycel — total revenues has grown at a -30.5% compound annual growth rate (CAGR), from $2.12B to $494M.
- What does sprycel — total revenues mean?
- This metric represents the total global net sales generated from the pharmaceutical product Sprycel, a tyrosine kinase inhibitor used primarily for the treatment of chronic myeloid leukemia. As a key oncology asset, revenue performance here reflects the drug's market penetration, competitive positioning against generic alternatives, and the overall lifecycle stage of the product within the company's hematology portfolio. Monitoring this revenue stream is essential for assessing the stability of the company's established oncology franchise.
Ask your AI about Bristol-Myers Squibb's sprycel — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude